Comparison between Q-Line Biotec IPO and Universal Contractors & Engineers IPO.
Q-Line Biotec IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Universal Contractors & Engineers IPO is a SME Bookbuilding proposed to list at NSE SME.
The total issue size of Q-Line Biotec IPO is up to ₹203.74 Cr whereas the issue size of the Universal Contractors & Engineers IPO is up to ₹0.00 Cr. The final issue price of Q-Line Biotec IPO is ₹343.00 per share and of Universal Contractors & Engineers IPO is .
| Q-Line Biotec IPO | Universal Contractors & Engineers IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹326.00 per share | |
| Issue Price (Upper) | ₹343.00 per share | |
| Issue Price (Final) | ₹343.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 400 shares | |
| Fresh Issue Size | 59,40,000 shares | 49,93,200 shares |
| Fresh Issue Size (Amount) | up to ₹203.74 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 59,40,000 shares | 49,93,200 shares |
| Issue Size Total (Amount) | up to ₹203.74 Cr | up to ₹0.00 Cr |
Q-Line Biotec IPO opens on May 21, 2026, while Universal Contractors & Engineers IPO opens on . The closing date of Q-Line Biotec IPO and Universal Contractors & Engineers IPO is May 25, 2026, and , respectively.
| Q-Line Biotec IPO | Universal Contractors & Engineers IPO | |
|---|---|---|
| Anchor Bid Date | May 20, 2026 | |
| Issue Open | May 21, 2026 | |
| Issue Close | May 25, 2026 | |
| Basis Of Allotment (Tentative) | May 26, 2026 | |
| Initiation of Refunds (Tentative) | May 27, 2026 | |
| Credit of Share (Tentative) | May 27, 2026 | |
| Listing date (Tentative) | May 29, 2026 | |
| Anchor Lockin End date 1 | Jun 25, 2026 | |
| Anchor Lockin End date 2 | Aug 24, 2026 |
Q-Line Biotec IPO P/E ratio is 20.82, as compared to Universal Contractors & Engineers IPO P/E ratio of .
| Q-Line Biotec IPO | Universal Contractors & Engineers IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 96.77 | 99.80 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 20.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹800.16 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 23.74 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 17.66 | 16.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.87 | 0.53 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹16.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 23.74 | 12.40 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Q-Line Biotec IPO Retail Individual Investors (RII) are offered 20,79,200 shares while in Universal Contractors & Engineers IPO retail investors are offered 20,79,200 shares. Qualified Institutional Buyers (QIB) are offered 11,88,000 shares in Q-Line Biotec IPO and 0 shares in Universal Contractors & Engineers IPO.
| Q-Line Biotec IPO | Universal Contractors & Engineers IPO | |
|---|---|---|
| Anchor Investor Reservation | 17,81,200 shares | 0 shares |
| Market Maker Reservation | 3,13,200 shares | 0 shares |
| QIB | 11,88,000 shares | 0 shares |
| NII | 8,91,600 shares | 0 shares |
| RII | 20,79,200 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 59,40,000 shares | 0 shares |
Q-Line Biotec IPO subscribed 71.71x in total, whereas Universal Contractors & Engineers IPO subscribed .
| Q-Line Biotec IPO | Universal Contractors & Engineers IPO | |
|---|---|---|
| QIB (times) | 123.94x | |
| NII (times) | 145.98x | |
| Big NII (times) | 178.29x | |
| Small NII (times) | 81.35x | |
| RII (times) | 71.44x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 71.71x |
